Immunocore Holdings plc

Greetings. Welcome to the Immunocore second quarter 2023 financial results and business update conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the call, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. At this time, I would like to hand the call over to Clayton Robertson, head of investor relations. Thank you. You may begin.

Thank you.

During today's call, we'll be making certain forward-looking statements, including about financial projections, development activities, business strategy, and the timing and impact of future events. Actual results could differ materially from those projected by these statements, which are based on management's views as of today and separate to risk and uncertainties, including those noted in our most recent Form 20F and ME6Ks we filed with the SEC in the earnings press release we issued this morning. Your caution not to place under-reliance on these statements, and Immunicard disclaims any obligation to update them. We'll also disclose certain non-IFRS measures on today's call, which are reconciled to comparable IFRS measures in today's slides. I will now hand over the call to our CEO, Dr. Berheja Tilal.